Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
JY Lee, SH Lim, M Kim, S Kim, HA Jung… - Cancer chemotherapy …, 2014 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations
N Koyama, Y Uchida - Anticancer Research, 2013 - ar.iiarjournals.org
Background: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
[HTML][HTML] Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor …
Results We analyzed 422 patients with EGFR-mutated advanced lung adenocarcinoma
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of …
T Shukuya, T Takahashi, R Kaira, A Ono… - Cancer …, 2011 - Wiley Online Library
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring …
CM Tsai, JT Chen, CH Chiu, CL Lai, SY Hsiao… - Lung Cancer, 2013 - Elsevier
Background Combined epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-
TKI) with chemotherapy is believed to be more effective in treating non-small-cell lung …
TKI) with chemotherapy is believed to be more effective in treating non-small-cell lung …
[HTML][HTML] Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized …
Background EGFR mutation might be a predictive factor for applying EGFR-tyrosine kinase
inhibitors (EGFR-TKIs, including gefitinib, erlotinib and afatinib) in non-small-cell lung …
inhibitors (EGFR-TKIs, including gefitinib, erlotinib and afatinib) in non-small-cell lung …
Phase II study of the EGFR-TKI rechallenge With Afatinib in patients with advanced NSCLC harboring sensitive EGFR mutation without T790M: Okayama lung cancer …
N Oda, E Ichihara, K Hotta, K Ninomiya, T Ninomiya… - Clinical Lung Cancer, 2017 - Elsevier
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy
for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a …
for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
JY Wu, SG Wu, CH Yang, YL Chang, YC Chang… - Lung cancer, 2011 - Elsevier
INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …